Want to see RCUS full AI Analyst Report?
RCUS Stock Chart & Stats
$24.25
-$0.04(-0.26%)
At close: 4:00 PM EST
$24.25
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$7.91 - $28.72
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.04M
Market Cap
$3.90B
Enterprise Value$2.34B
Total Cash (Recent Filing)$822.00M
Total Debt (Recent Filing)$113.00M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 12, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.17
Shares Outstanding125,773,160
10 Day Avg. Volume1,313,431
30 Day Avg. Volume1,040,235
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue9.92
Enterprise Value/Gross Profit10.22
Enterprise Value/Ebitda-7.09
Forecast
1Y Price Target
$36.75Price Target Upside51.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$86.14M
Bulls Say, Bears Say
Bulls Say
Balance Sheet / Cash RunwayArcus’s ~$876M cash position and stated runway into at least 2028 provide durable funding visibility to complete registrational trials and prioritized programs. This reduces near‑term dilution risk, enables disciplined execution of 2026–2027 catalysts, and supports commercialization planning.
Clinical Differentiation — Cascadifan EfficacyCascadifan’s materially longer PFS and improved ORR versus a comparator signal a meaningful clinical differentiation that can support regulatory approval, stronger label positioning and payer arguments. Durable efficacy materially raises the probability of commercial uptake in IO‑experienced and frontline settings.
Portfolio Prioritization And Spend DisciplineManagement’s reallocation of >80% of portfolio spend to cascadifan plus a ~10% workforce reduction demonstrates focused capital allocation. This increases the odds of success for the lead asset, lowers non‑core burn, and structurally improves runway and resource efficiency through 2026–2027.
Bears Say
Sustained Cash Burn And Negative FCFPersistent, large negative operating and free cash flow signal structural funding dependence. Until there is material revenue from marketed products or materially lower R&D spend, Arcus will likely need external financing or partnerships, creating dilution risk and constraining strategic flexibility.
Late‑stage Program DiscontinuationStopping STAR‑121 eliminates a late‑stage asset and represents lost prior investment and near‑term milestone potential. This reduces the company’s late‑stage optionality, increases reliance on remaining pivotal trials (e.g., PEEK‑1) for value, and can slow near‑term revenue/milestone prospects.
Partnership Reset And Reduced Option RightsGilead’s decision not to continue options limits external co‑development and milestone funding for several programs. Reduced partner optionality shifts more execution and commercialization risk onto Arcus, potentially increasing financing needs and complicating global development or market access strategies.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences’s price range in the past 12 months?
Arcus Biosciences lowest stock price was $7.91 and its highest was $28.72 in the past 12 months.
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $3.90B.
When is Arcus Biosciences’s upcoming earnings report date?
Arcus Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 44 days.
How were Arcus Biosciences’s earnings last quarter?
Arcus Biosciences released its earnings results on May 05, 2026. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.14.
Is Arcus Biosciences overvalued?
According to Wall Street analysts Arcus Biosciences’s price is currently Undervalued.
Does Arcus Biosciences pay dividends?
Arcus Biosciences does not currently pay dividends.
What is Arcus Biosciences’s EPS estimate?
Arcus Biosciences’s EPS estimate is -0.89.
How many shares outstanding does Arcus Biosciences have?
Arcus Biosciences has 125,773,160 shares outstanding.
What happened to Arcus Biosciences’s price movement after its last earnings report?
Arcus Biosciences reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -0.23%.
Which hedge fund is a major shareholder of Arcus Biosciences?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.75 (51.55% Upside)
$36.75 (51.55% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 394.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
264.70%
12-Months-Change
Fundamentals
Return on Equity
-68.97%
Trailing 12-Months
Asset Growth
-13.75%
Trailing 12-Months
Company Description
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS Company Deck
RCUS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical differentiation and durable efficacy for cascadifan (notably improved ORR and substantially longer PFS versus a competitor), accelerating enrollment in the registrational PEEK-1 study, a solid cash position with runway into 2028, and a rapidly advancing I&I small-molecule pipeline (AB-102 and others). Offsetting these positives were a late-stage program discontinuation (STAR-121), competitor frontline/triplet failures that create class-level caution, and high near-term R&D spend in Q1 (with nonrecurring costs and a ~10% headcount reduction). On balance, the company presented multiple high-value catalysts, clear prioritization of cascadifan, and a strong balance sheet to execute—outweighing the program setbacks and near-term expense noise.View all RCUS earnings summariesRCUS Stock 12 Month Forecast
Average Price Target
$36.75
▲(51.55% Upside)
Technical Analysis
Ownership Overview
4.39% Insiders
14.74% Mutual Funds
45.92% Other Institutional Investors
15.94% Public Companies and
Individual Investors